Prostate Cancer - Results from #27700

Picking the optimal treatment for patients with metastatic castration resistant prostate cancer - Slide Presentation June 13, 2011

Abiraterone and increased survival in metastatic prostate cancer - Abstract June 12, 2011

A short-term cost-effectiveness study comparing robot-assisted laparoscopic and open retropubic radical prostatectomy - Abstract June 11, 2011

The contemporary concept of significant versus insignificant prostate cancer - Abstract June 10, 2011

A population-based study of prostate cancer chemotherapy - Abstract June 10, 2011

Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21 - Abstract June 10, 2011

Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer - Abstract June 10, 2011

From prostate to bone: Key players in prostate cancer bone metastasis - Abstract June 10, 2011

Rapid increase of the serum PSA level in response to high-intensity focused ultrasound therapy may be a potential indicator of biochemical recurrence of low- and intermediate-risk prostate cancer - Abstract June 10, 2011

Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer - Abstract June 10, 2011

Prostate cancer imaging: What surgeons, radiation oncologists, and medical oncologists want to know - Abstract June 10, 2011

The utility of 11C-choline PET/CT for imaging prostate cancer: A pictorial guide - Abstract June 10, 2011

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen - Abstract June 10, 2011

Editor's Commentary - Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer June 10, 2011

Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients June 10, 2011

Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis - Abstract June 9, 2011

Combination chemotherapy of docetaxel and UFT against hormone refractory prostate cancer - Abstract June 9, 2011

Specialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort - Abstract June 9, 2011

EPLIN is a negative regulator of prostate cancer growth and invasion - Abstract June 9, 2011

Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy - Abstract June 9, 2011

Page 1386 of 1435